PharmaBoardroom

PharmaBoardroom’s Top Five Op-Eds of 2021

PharmaBoardroom's network of thought leaders provided some of our best-read content in 2021 on topics ranging from China's National Reimbursement Drug…

Amr Seif – Area Lead Middle East & Africa (MEA),…

Amr Seif introduces the evolution in Astellas' MEA strategy; the adoption of innovative access models to ensure that the companies' therapies are…

Amr El-Neklawy – SVP MENA FWA PAT, Emcure

Emcure’s Senior VP for the Middle East, North & West Africa, Afghanistan, Pakistan & Turkey, Amr El-Neklawy, highlights the level of…

PharmaBoardroom’s 10 Most Read Interviews of 2021

PharmaBoardroom’s ten most-read executive interviews of 2021 reflect the wide scope – in terms of both geography and value chain – that our work…

Genmab CEO On 50:50 Partnerships & Creating “Iconic”…

Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap…

Abogen: Billion Dollar 2021 for China’s Thermostable mRNA Hope

The phenomenal success of the Pfizer/BioNTech and Moderna COVID-19 vaccines has catapulted messenger RNA (mRNA) vaccines into public consciousness,…

Jan van de Winkel – President & CEO, Genmab

Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over…

A ‘Bold Vision’ of CAR-T Patient Engagement

Marc Boutin, Novartis’ global head of patient engagement, outlines the company’s “bold vision” of patient engagement and the actions that need…

Rare Diseases in MENA and the Need for Infrastructure, Access…

Few stakeholders are better placed to assess the landscape for rare disease therapies across the Middle East and North Africa (MENA) region than Karim…